A Review of the Carbapenems in Clinical Use and Clinical Trials

Title: A Review of the Carbapenems in Clinical Use and Clinical Trials

Volume: 3 Issue: 2

Author(s): Tze S. Lo, Justin M. Welch, Augusto M. Alonto and Eileen A.R. Vicaldo-Alonto

Affiliation:

Keywords: Carbapenems, new agents, resistant organisms, nosocomial infection, broad spectrum

Abstract: Despite alarming data showing the ever increasing number of bacteria becoming resistant to different classes of antibiotics through various mechanisms, the carbapenems remain a unique class of antibiotics that possess the broadest spectrum against Gram-positive, Gram-negative, aerobic and anaerobic organisms. However, bacteria, such as methicillinresistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, carry mechanisms that can inactivate the carbapenems. This article gives a review of the carbapenems that are currently in clinical use as well as discusses the new carbapenems that are in clinical trials. These new carbapenems show promising potential to overcome the resistance against the presently existing carbapenems. The present article shows the recent patents using carbapenems as an effective antibiotic.

Cite this article as:

Lo S. Tze, Welch M. Justin, Alonto M. Augusto and Vicaldo-Alonto A.R. Eileen, A Review of the Carbapenems in Clinical Use and Clinical Trials, Recent Patents on Anti-Infective Drug Discovery 2008; 3 (2) . https://dx.doi.org/10.2174/157489108784746588